Table 3

Bone marrow transplantation

Patient Type of BMT (nucleated cells/kg) Age at BMT Conditioning Engraftment Complications
1Parental (1)2.3 yearsBu 16 Cy 200NoGraft rejection
CyA AZX
MUD (2)YesAlive and well at 5 years
(5.0 × 108/kg)
4HLA identical MSD15.6 yearsBu 16 Cy 200YesCMV/adenovirus pneumonitis
(3.9 × 108/kg)CyA AZXCryptosporidium
(died D +93)
7HLA identical paternal uncle7 monthsCampath 1G (D −10 to −6)NoAcute renal failure (Foscarnet)
(4.0 × 108/kg)Bu 20 Cy 200Toxic epidermal necrolysis
CyADisseminated CMV
(died D +17)
8HLA identical great uncle (1)1 monthBu 16 Cy 200Yes transient (D +21)Transplant associated pneumonitis
(11.5 × 108/kg)ATG (D −4 to −1)Transplant rejection
DQ mismatched paternal uncle (2)CyA, MTX×3
(T cell depleted)5 monthsBu 20 Cy 200Yes (D +14)Transplant associated pneumonitis
(5.5 × 108/kg)anti-LFA-1/CD2Rotavirus enteritis
(D −3 to +10)(died D +87)
9HLA identical sister6 monthsBu 20 Cy 200NoParainfluenza III pneumonitis
(7.8 × 108/kg)CyA MTX×2(died D +19)
10HLA identical father6 yearsFlu, MelYesSevere gastroenteritis
(whole marrow)Cryptosporidium, adeno CMV viraemia
(8.4 × 108/kg)(asymptomatic)
(alive 5 months post-BMT)
  • Bu 20, busulphan total dose 20 mg/kg given as 4 divided doses (5 mg/kg) over 4 days; Cy 200, cyclophosphamide total dose 200 mg/kg given as 4 divided doses (50 mg/kg) over 4 days; AZX, azathioprine; MTX, methotrexate; Flu, fludarabine 30 mg/m2; Mel, melphalan 140 mg/m2.